Loading
The Milan System puts the result of a needle test on a salivary gland lump into one of six categories, each with its own risk of cancer and its own next step.
The Milan System for Reporting Salivary Gland Cytopathology was first published in 2018. It defines six diagnostic categories for fine-needle aspiration covering non-neoplastic, benign and malignant lesions, and pairs each with a risk of malignancy and a clinical or surgical management algorithm. The second edition, July 2023 (Rossi and colleagues, Cytopathology), refines the risks from systematic reviews and meta-analyses, adds salivary gland imaging and ancillary testing, and updates nomenclature.
Showing the technology this term belongs to: Thyroid nodule FNA, Bethesda cytology & molecular classifiers.
Shares WHO Reporting Systems for cytopathology, Bethesda category (thyroid cytology), Core needle biopsy and fine-needle aspiration (FNA).
Shares WHO Reporting Systems for cytopathology, Bethesda category (thyroid cytology), Core needle biopsy and fine-needle aspiration (FNA).
Shares Bethesda category (thyroid cytology), Thyroid nodule FNA, Bethesda cytology & molecular classifiers.
Shares WHO Reporting Systems for cytopathology, Bethesda category (thyroid cytology).
Shares WHO Reporting Systems for cytopathology, Bethesda category (thyroid cytology).
Shares Bethesda category (thyroid cytology), Thyroid nodule FNA, Bethesda cytology & molecular classifiers.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/